Hemoglobin‐platelet index as a prognostic factor in patients with peripheral T‐cell lymphoma
Abstract Peripheral T‐cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with a poor prognosis. The International Prognostic Index (IPI) and the Prognostic Index for PTCL‐unspecified (PIT) is used to predict the prognosis of PTCL. The hemoglobin‐platelet index (HPI), based on anem...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.727 |
| _version_ | 1827818400027508736 |
|---|---|
| author | Yu Yagi Yusuke Kanemasa Yuki Sasaki Shunichi Okumura Takako Watanabe Kento Ishimine Yudai Hayashi Mano Mino An Ohigashi Yuka Morita Taichi Tamura Shohei Nakamura Toshihiro Okuya Tatsu Shimoyama |
| author_facet | Yu Yagi Yusuke Kanemasa Yuki Sasaki Shunichi Okumura Takako Watanabe Kento Ishimine Yudai Hayashi Mano Mino An Ohigashi Yuka Morita Taichi Tamura Shohei Nakamura Toshihiro Okuya Tatsu Shimoyama |
| author_sort | Yu Yagi |
| collection | DOAJ |
| description | Abstract Peripheral T‐cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with a poor prognosis. The International Prognostic Index (IPI) and the Prognostic Index for PTCL‐unspecified (PIT) is used to predict the prognosis of PTCL. The hemoglobin‐platelet index (HPI), based on anemia and thrombocytopenia status, is associated with the prognosis of diffuse large B‐cell lymphoma. However, its significance in terms of predicting the prognosis of PTCL has not been fully investigated. We herein retrospectively analyzed 100 patients with newly diagnosed PTCL in our department. At a median follow‐up of 3.2 years, the median progression‐free survival (PFS) and overall survival (OS) was 0.72 (95% confidence interval [CI]: 0.56–1.2) years and 2.0 (95% CI: 1.5–4.7) years, respectively. Multivariate analysis revealed that elevated lactic dehydrogenase (LDH) and hypoalbuminemia were independent adverse variables for PFS. The HPI showed significant predictive value for both PFS and OS. As a new prognostic model comprising the HPI, LDH, and albumin, the LA‐HPI allowed the stratification of patients into four distinct risk subgroups: low risk (zero risk factors), low‐intermediate risk (one risk factors), high‐intermediate risk (two or three risk factors), or high risk (four risk factors). The PFS and OS differed significantly among the patients by the LA‐HPI score. The LA‐HPI demonstrated better predictive performance compared to the IPI, PIT, and HPI. Our data demonstrated the prognostic utility of the HPI in patients with PTCL. The LA‐HPI, incorporating four readily obtainable parameters, exhibited superior performance compared to traditional indices. |
| first_indexed | 2024-03-12T00:47:12Z |
| format | Article |
| id | doaj.art-887794c9211c4cb9822d6a349d958f26 |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-12T00:47:12Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-887794c9211c4cb9822d6a349d958f262023-09-14T15:30:47ZengWileyeJHaem2688-61462023-08-014365666610.1002/jha2.727Hemoglobin‐platelet index as a prognostic factor in patients with peripheral T‐cell lymphomaYu Yagi0Yusuke Kanemasa1Yuki Sasaki2Shunichi Okumura3Takako Watanabe4Kento Ishimine5Yudai Hayashi6Mano Mino7An Ohigashi8Yuka Morita9Taichi Tamura10Shohei Nakamura11Toshihiro Okuya12Tatsu Shimoyama13Department of Medical Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Medical Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Medical Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Pharmacy Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Pharmacy Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Medical Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Medical Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Medical Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Medical Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Medical Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Medical Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Medical Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Medical Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanDepartment of Medical Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo JapanAbstract Peripheral T‐cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with a poor prognosis. The International Prognostic Index (IPI) and the Prognostic Index for PTCL‐unspecified (PIT) is used to predict the prognosis of PTCL. The hemoglobin‐platelet index (HPI), based on anemia and thrombocytopenia status, is associated with the prognosis of diffuse large B‐cell lymphoma. However, its significance in terms of predicting the prognosis of PTCL has not been fully investigated. We herein retrospectively analyzed 100 patients with newly diagnosed PTCL in our department. At a median follow‐up of 3.2 years, the median progression‐free survival (PFS) and overall survival (OS) was 0.72 (95% confidence interval [CI]: 0.56–1.2) years and 2.0 (95% CI: 1.5–4.7) years, respectively. Multivariate analysis revealed that elevated lactic dehydrogenase (LDH) and hypoalbuminemia were independent adverse variables for PFS. The HPI showed significant predictive value for both PFS and OS. As a new prognostic model comprising the HPI, LDH, and albumin, the LA‐HPI allowed the stratification of patients into four distinct risk subgroups: low risk (zero risk factors), low‐intermediate risk (one risk factors), high‐intermediate risk (two or three risk factors), or high risk (four risk factors). The PFS and OS differed significantly among the patients by the LA‐HPI score. The LA‐HPI demonstrated better predictive performance compared to the IPI, PIT, and HPI. Our data demonstrated the prognostic utility of the HPI in patients with PTCL. The LA‐HPI, incorporating four readily obtainable parameters, exhibited superior performance compared to traditional indices.https://doi.org/10.1002/jha2.727albuminhemoglobin‐platelet indexlactate dehydrogenaseperipheral T‐cell lymphomaprognostic factorsurvival |
| spellingShingle | Yu Yagi Yusuke Kanemasa Yuki Sasaki Shunichi Okumura Takako Watanabe Kento Ishimine Yudai Hayashi Mano Mino An Ohigashi Yuka Morita Taichi Tamura Shohei Nakamura Toshihiro Okuya Tatsu Shimoyama Hemoglobin‐platelet index as a prognostic factor in patients with peripheral T‐cell lymphoma eJHaem albumin hemoglobin‐platelet index lactate dehydrogenase peripheral T‐cell lymphoma prognostic factor survival |
| title | Hemoglobin‐platelet index as a prognostic factor in patients with peripheral T‐cell lymphoma |
| title_full | Hemoglobin‐platelet index as a prognostic factor in patients with peripheral T‐cell lymphoma |
| title_fullStr | Hemoglobin‐platelet index as a prognostic factor in patients with peripheral T‐cell lymphoma |
| title_full_unstemmed | Hemoglobin‐platelet index as a prognostic factor in patients with peripheral T‐cell lymphoma |
| title_short | Hemoglobin‐platelet index as a prognostic factor in patients with peripheral T‐cell lymphoma |
| title_sort | hemoglobin platelet index as a prognostic factor in patients with peripheral t cell lymphoma |
| topic | albumin hemoglobin‐platelet index lactate dehydrogenase peripheral T‐cell lymphoma prognostic factor survival |
| url | https://doi.org/10.1002/jha2.727 |
| work_keys_str_mv | AT yuyagi hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma AT yusukekanemasa hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma AT yukisasaki hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma AT shunichiokumura hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma AT takakowatanabe hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma AT kentoishimine hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma AT yudaihayashi hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma AT manomino hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma AT anohigashi hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma AT yukamorita hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma AT taichitamura hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma AT shoheinakamura hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma AT toshihirookuya hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma AT tatsushimoyama hemoglobinplateletindexasaprognosticfactorinpatientswithperipheraltcelllymphoma |